Search Results
10
Everything
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
March 18, 2025 09:00 ET
|
Femasys Inc.
-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® -- ATLANTA, March 18, 2025 (GLOBE NEWSWIRE)...
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
March 13, 2025 08:30 ET
|
Femasys Inc.
ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of...
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
February 25, 2025 09:20 ET
|
Femasys Inc.
--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- ATLANTA, Feb. 25, 2025 ...
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
February 11, 2025 09:00 ET
|
Femasys Inc.
ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of...
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
January 30, 2025 08:30 ET
|
Femasys Inc.
ATLANTA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of...
Bonafide® Health Launches Thermella™, The First and Only Hormone-Free, Prescription-Free NK3R Antagonist for Menopause Symptom Management – Delivers Groundbreaking Clinical Research at The Menopause Society’s Annual Meeting
September 23, 2024 09:00 ET
|
Bonafide® Health, LLC
New York, NY, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Bonafide Health, LLC, a women’s healthcare company committed to providing effective and clinically studied solutions for common perimenopause and...
Bonafide Health Issues Findings of 4th Annual State of Menopause Study, Trends Reveal Positive Progress in Open Discussion and Overcoming Stigma, But Confusion and Misperceptions Remain Rampant
July 08, 2024 08:50 ET
|
Bonafide® Health, LLC
New York, NY, July 08, 2024 (GLOBE NEWSWIRE) -- Bonafide Health, LLC, a women’s healthcare company that provides hormone-free, clinically researched solutions to effectively relieve perimenopause...
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
April 18, 2024 08:30 ET
|
Femasys Inc.
ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
Bonafide Health’s 3rd Annual 'State of Menopause' Survey Reveals Startling Lack of Menopause Education
October 11, 2023 08:50 ET
|
Bonafide® Health, LLC
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bonafide® Health, LLC, a women’s healthcare company offering naturally powerful solutions to manage common perimenopause and menopause symptoms,...
Penn Highlands Healthcare Physician Performs Innovative Hysterectomy Surgery
October 13, 2022 09:49 ET
|
Penn Highlands Healthcare
DuBois, Pennsylvania, Oct. 13, 2022 (GLOBE NEWSWIRE) -- There was a time that if a woman needed a hysterectomy she could expect a hospital stay followed by an at-home recovery time of four to six...